Alzheimer’s disease

Screening of a Fraction with Higher Amyloid β Aggregation Inhibitory Activity from a Library Containing 210 Mushroom Extracts Using a Microliter-Scale High-Throughput Screening System with Quantum Dot Imaging

mycolabadmin

Researchers screened 210 mushroom species from Japan to find those that could prevent harmful protein clumping in the brain associated with Alzheimer’s disease. They identified a purified fraction from the mushroom Elfvingia applanata that was more effective than a known anti-Alzheimer’s compound at stopping these protein clumps from forming. The extract also protected nerve cells from damage in laboratory tests. This finding suggests mushrooms could potentially be developed into a functional food to help prevent Alzheimer’s disease.

Isolation and Evaluation of Erinacine A Contents in Mycelia of Hericium erinaceus Strains

mycolabadmin

Researchers developed a new method to extract and purify erinacine A, a beneficial compound from lion’s mane mushrooms, using an advanced separation technique called high-speed countercurrent chromatography. They tested 15 different mushroom strains and found that a wild strain called HeG produced significantly more erinacine A than commercially cultivated varieties. Erinacine A shows promise for protecting brain health and potentially helping with diseases like Alzheimer’s and Parkinson’s. This discovery could help make erinacine A supplements more accessible and affordable for consumers.

Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders

mycolabadmin

Mushrooms contain special compounds that may help protect our brains as we age. These fungal compounds fight inflammation, reduce harmful free radicals, and help clear out damaged cellular parts—all things that slow down brain aging and diseases like Alzheimer’s and Parkinson’s. While the research looks very promising in lab and animal studies, scientists still need to figure out how to make these compounds work better in the human body and prove they’re safe and effective in patients.

Efficacy and safety of MT104, a dietary supplement based on Cuscuta seeds and heat‐killed probiotics, on cognitive function in patients with mild cognitive impairment: A 12‐week, multicenter, randomized, double‐blind, placebo‐controlled clinical trial

mycolabadmin

Researchers tested a dietary supplement called MT104 made from Cuscuta seeds and special probiotics to see if it could improve memory and thinking in people with mild cognitive impairment, an early stage before dementia develops. In a 12-week study with 200+ participants, those taking MT104 showed better memory recall and overall cognitive function compared to those taking a placebo. The supplement appeared to be safe with no serious side effects, suggesting it could be a helpful natural approach to slow the progression toward Alzheimer’s disease.

Bioactive Potential of Balkan Fomes fomentarius Strains: Novel Insights into Comparative Mycochemical Composition and Antioxidant, Anti-Acetylcholinesterase, and Antiproliferative Activities

mycolabadmin

This study examines three strains of Fomes fomentarius mushroom from the Balkan region, revealing they are rich sources of beneficial compounds including polyamines and phenolic compounds. These extracts demonstrated strong antioxidant properties and potential neuroprotective effects, suggesting they could help prevent diseases related to oxidative stress and aging. The research supports the traditional use of this mushroom in folk medicine and highlights its potential as a natural supplement for health promotion.

Neuroprotective Effects of Mushroom Biomass Digestive Fractions and Gut Microbiota Metabolites in Microglial and Caenorhabditis elegans Models of Neurodegeneration

mycolabadmin

This study tested whether common and medicinal mushrooms could protect against Alzheimer’s disease by reducing harmful reactive oxygen species in brain cells. Researchers tested three mushroom types using digestive simulation to see what the body could absorb, plus key compounds made by gut bacteria. The mushroom extracts and certain bacterial metabolites successfully reduced cellular damage markers and improved behavior in disease-model worms, suggesting mushroom-rich diets may help prevent neurodegeneration.

Screening of active components of Ganoderma lucidum and decipher its molecular mechanism to improve learning and memory disorders

mycolabadmin

Researchers used computer analysis and laboratory experiments to understand how a medicinal mushroom called Ganoderma lucidum (reishi) helps improve memory and learning problems. They identified ten key active ingredients in the mushroom that work together to reduce inflammation in the brain and protect nerve cells. The most important ingredient appears to be a compound called β-sitosterol, which helps prevent memory loss similar to effects seen in Alzheimer’s disease.

Sporoderm-removed ganoderma lucidum spore powder (S-GLSP) alleviates neuroinflammation injury by regulating microglial polarization through inhibition of NLRP3 inflammasome activation

mycolabadmin

Researchers found that sporoderm-removed Ganoderma lucidum spore powder (S-GLSP) protects against Alzheimer’s disease by reducing brain inflammation. The supplement works by shifting immune cells in the brain called microglia from a harmful pro-inflammatory state to a protective anti-inflammatory state. This is accomplished by blocking the NLRP3 inflammasome, a key trigger of brain inflammation. In animal and cell studies, S-GLSP improved memory, reduced neuronal damage, and decreased harmful tau protein accumulation.

Assessment of Lab4P Probiotic Effects on Cognition in 3xTg-AD Alzheimer’s Disease Model Mice and the SH-SY5Y Neuronal Cell Line

mycolabadmin

Researchers tested a probiotic supplement called Lab4P on mice genetically engineered to develop Alzheimer’s-like symptoms and on human brain cells exposed to damaging proteins. The supplement successfully improved memory and cognitive function in the mice while protecting brain cells from damage, with stronger benefits when the mice were also on a high-fat diet. These findings suggest that probiotics might help prevent or slow cognitive decline related to Alzheimer’s disease.

Microbial links to Alzheimer’s disease

mycolabadmin

Researchers are investigating whether common infections from bacteria, viruses, and fungi might trigger or worsen Alzheimer’s disease. Studies show that pathogens like the bacteria that causes gum disease and certain herpes viruses can reach the brain and trigger inflammation and amyloid-beta accumulation, key features of Alzheimer’s. While the evidence is promising, scientists haven’t yet proven whether these infections cause Alzheimer’s or simply make existing disease worse.

Research Keyword: Alzheimer's disease